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Absolute monocyte count at diagnosis could improve the
prognostic role of early FDG-PET in classical Hodgkin
lymphoma patients
Recently published international guidelines suggested that
positron emission tomography (PET)-computed tomography
(CT) could be utilized for response assessment using the
Deauville criteria in fluorodeoxyglucose (FDG)-avid lym-
phomas (Meignan et al, 2012). Interim PET (I-PET) scan-
ning seems highly predictive of treatment failure in Hodgkin
Lymphoma (HL) patients.
We recently showed that the absolute monocyte count
(AMC) has prognostic value in patients with classical HL
(cHL) (Tadmor et al, 2015). Here, we show that the com-
bined use of I-PET and AMC at diagnosis enables a more
accurate projection of patient outcome in cHL.
The present study is an ancillary branch of the analysis
reported by Tadmor et al, (2015). Patients with histopatho-
logical diagnosis of cHL previously enrolled in the Gruppo
Italiano Studio Linfomi trials were eligible if data on all clini-
cal and laboratory features and treatments, reported I-PET
results, treatment response and follow-up were available.
Response was defined according to the revised International
Working Group guidelines (Cheson et al, 1999). An absolute
lymphocyte count <06 9 109/l and AMC > 075 9 109/l
were used as cut-off points. I-PET was performed after 2
cycles of treatment. A positive or negative I-PET was defined
by the local investigators’ interpretation of the nuclear physi-
cian’s scan report, which was based on a visual qualitative
assessment.
The principal end-point of the study was the impact of
I-PET and AMC on progression-free survival (PFS); their
impact on overall survival (OS) was the secondary end-point.
Survival functions were estimated using the Kaplan–Meier
method. Statistical comparisons between curves were per-
formed with log-rank test, and the effect of the covariate was
reported as hazard ratios (HR), from Cox regression.
All patients had a diagnosis of cHL; 76% of cases had the
nodular sclerosis (NS) subtype. Seventy-six patients (64%)
were treated with classical ABVD (doxorubicin, bleomycin,
vincristine, dacarbazine), and 23 (19%) and 19 (16%) with
the more intensive BEACOPP (bleomycin, etoposide, doxoru-
bicin, cyclophosphamide, vincristine, procarbazine, pred-
nisone) and COPPEBVCAD (cyclophosphamide, lomustine,
vindesine, melphalan, prednisone, epidoxirubicin, vincristine,
procarbazine, vinblastine, bleomycin) regimens (Federico
et al, 2009), respectively. Of the entire cohort, 104 patients
(88%) achieved complete remission. Twenty-six patients had
a positive I-PET (22%) and 28 (24%) had AMC > 075 9
109/l at diagnosis.
The median follow-up of the entire cohort was 88 months
(range 5–142 months). The estimated 5-year OS was 91%
(95% confidence interval [CI]: 84–95%). The 5-year PFS was
80% (95% CI: 71–86%). Patients with positive I-PET showed
a worse PFS compared to patients with negative I-PET (51%
and 88%, respectively; HR 587 [95% CI: 256–135]).
Patients with AMC > 075 9 109/l at diagnosis had a worse
PFS compared to patients with AMC ≤ 075 9 109/l (58%
and 87%, respectively; HR 373 [95% CI: 161–864]). Multi-
ple Cox proportional hazards (PH) regression, adjusted for
International Prognostic Score 3–7, confirmed the prognostic
role of I-PET (HR 532 [95% CI: 230–123]; P < 0001) and
AMC >075 9 109/l (HR 319 [95% CI: 132–768];
P = 0010). Figure 1A, B shows the PFS for I-PET and AMC,
and Table I shows the uni- and multivariate Cox PH regres-
sion for PFS. The prognostic role of I-PET and AMC on OS
was also confirmed.
Given the strong predictive value of both I-PET and
AMC, we stratified patients by positive or negative I-PET
and AMC > 075 9 109/l or ≤075 9 109/l into 3 groups
with different levels of risk. The low risk level (negative I-
PET and AMC ≤ 075 9 109/l; n = 73, 62%) had a 5-year
PFS of 90% (95% CI: 80–96%), the intermediate level
(I-PET positive or AMC > 075 9 109/l; n = 36, 51%) had a
5-year PFS of 73% (95% CI: 55–85%), and the high risk level
(I-PET positive and AMC > 075 9 109/l; n = 9, 8%) had a
5-year PFS of 17% (95% CI: 1–49%). The log-rank test
between the intermediate and low levels and between the
high and intermediate levels were significant (P = 0007,
P = 0001, respectively). For OS, the difference between the
intermediate and low risk levels tended to narrow
(P = 0232), while the difference between the high and inter-
mediate levels was significantly different (P < 0001). Fig-
ure 1C, D shows the PFS and OS stratified by risk group.
The test for trend in PFS and OS was significant
(P < 0001).
The rationale for using AMC as a prognostic parameter in
cHL is relevant because immunohistochemical and molecular
data, including the gene expression profile, have identified a
key role for monocytes and macrophages in the biology of
cHL (Steidl et al, 2010; Porrata et al, 2012; Tan et al, 2012;
Koh et al, 2015; Tadmor et al, 2015). It might therefore be
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possible that AMC is associated with the number of tumour-
associated macrophages (TAMs) in the microenvironment. If
so, then it could be considered as a biomarker of reactive
cells that is easily detectable in peripheral blood. The FDG-
PET scan is currently considered the most precise staging
method and may also be used to provide an early prediction
of treatment efficacy.
There is a strong suggestion that reactive cells are respon-
sible for the increased FDG uptake at baseline, as they
account for 99% of Hodgkin tumours (Gallamini, 2010).
Furthermore, early responses to treatment have been sug-
gested to demonstrate the elimination of reactive cells, or at
least the disappearance of their activity, and are indirect
surrogates of tumour chemo-sensitivity (Gallamini &
Kostakoglu, 2012). Thus, the FDG-PET scan could be
considered a biomarker of the extent and activity of the
tumour microenvironment.
However, in clinical practice, patients with negative I-PET
can rapidly progress during induction treatment, while other
patients with positive I-PET may eventually achieve a CR.
Therefore, there is a need to further improve the predictive
power of I-PET. By combining the AMC at diagnosis with
the I-PET results, we showed that it is possible to increase
the discriminatory power of I-PET alone in identifying cHL
patients with poor PFS and OS. We are fully aware that our
study has many weaknesses, such as its retrospective nature,
the small number of patients and the lack of use of the
Deauville criteria. However, our results suggest that it is pos-
sible to further improve the already high predictive power of
PET by combining it with a simple and inexpensive surrogate
biomarker of reactive cells that are easily detectable in
peripheral blood.
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Fig 1. (A) Progression-free survival (PFS)
stratified by interim- positron emission tomog-
raphy (PET); (B) PFS stratified by absolute
monocyte count (AMC); (C) PFS stratified by
combined interim-PET and AMC; (D) overall
survival (OS) stratified by combined interim-
PET and AMC.
Table I. Uni- and multivariate Cox proportional hazard regression
for progression-free survival (PFS).
5-year
PFS (%) HR 95% CI P-value
Univariate
I-PET Negative 88 100
Positive 51 587 256–135 <0001
AMC ≤075 9 109/l 87 100
>075 9 109/l 58 373 161 –864 0002
LMR >21 82 100
≤21 77 151 067 –343 0320
Stage I –IIA 93 100
IIB –IV 78 308 041 –229 0272
IPS 0 –2 83 100
3 –7 74 165 072 –376 0236
Histology NS 79 100
Other 81 108 043 –275 0864
Multivariate
I-PET No 100
Yes 532 230–123 <0001
AMC ≤075 9 109/l 100
>075 9 109/l 319 132–768 0010
IPS 0–2 100
3–7 109 046–261 0839
I-PET, interim positron emission tomography; AMC, absolute
monocyte count; LMR, lymphocyte to monocyte ratio; NS, nodular
sclerosis; HR, hazard ratio; CI, confidence interval.
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